Medical materials

Publication
  • ASN •
  • 8 November, 2025 •
  • •

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Carla M Nester, Fadi Fakhouri, Daniel P Gale, Andrew S Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Katie Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana-Gallardo, Matthew C Pickering

Available materials

Oral Presentation
Publication
  • ASN •
  • 7 November, 2025 •
  • •

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Bradley P Dixon, Andrew S Bomback, Carly Rich, Mingyi Huang, Piotr Wojciechowski, Rose Chang, Fernando Caravaca-Fontán, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 7 November, 2025 •
  • •

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Sanya Norouzi, Mingyi Huang, Carly Rich, Katie Gordon, Lucía Quintana-Gallardo, Elizabeth A Holdsworth, Fernando Caravaca-Fontán

Available materials

Poster
Publication
  • ASN •
  • 6 November, 2025 •
  • •

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Minesh Rajpal, Vibeke Strand, Rehan Azeem, Ben Peace, Bhavisha Desai, Richard J. Johnson

Available materials

Poster
Publication
  • ASN •
  • 6 November, 2025 •
  • •

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Hyon Choi, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Kenneth Saag

Available materials

Poster
Publication
  • ASN •
  • 6 November, 2025 •
  • •

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients With Uncontrolled Gout (UG) and Stage 3 CKD

Nissreen Elfadawy, Puja Khanna, Rehan Azeem, Ben Peace, Bhavisha Desai, Yasir Qazi

Available materials

Poster
Publication
  • ASN •
  • 5 November, 2025 •
  • •

Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis

Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 5 November, 2025 •
  • •

Human factors validation of a pegcetacoplan on-body injector demonstrates ease of use by adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis

Eliyahu Khankin, Chirayu Mehta, Chauncey Clemons

Available materials

Poster
Publication
  • ASN •
  • 5 November, 2025 •
  • •

Pegcetacoplan for adolescents and adults with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: Enrollment status of the VALE extension

Eliyahu Khankin, Carla M Nester, Gema Ariceta, Anwesha Mukherjee, Johan Szamosi, Luis López Lázaro

Available materials

Poster
Sign up for alerts